These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1064 related items for PubMed ID: 25900924

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Mepolizumab: First Global Approval.
    Keating GM.
    Drugs; 2015 Dec; 75(18):2163-9. PubMed ID: 26603873
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Reslizumab Compared with Benralizumab in Patients with Eosinophilic Asthma: A Systematic Literature Review and Network Meta-Analysis.
    Casale TB, Pacou M, Mesana L, Farge G, Sun SX, Castro M.
    J Allergy Clin Immunol Pract; 2019 Jan; 7(1):122-130.e1. PubMed ID: 30217529
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma.
    Matera MG, Calzetta L, Rinaldi B, Cazzola M.
    Expert Opin Drug Metab Toxicol; 2017 Sep; 13(9):1007-1013. PubMed ID: 28737051
    [Abstract] [Full Text] [Related]

  • 8. Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma.
    Sehmi R, Smith SG, Kjarsgaard M, Radford K, Boulet LP, Lemiere C, Prazma CM, Ortega H, Martin JG, Nair P.
    Clin Exp Allergy; 2016 Jun; 46(6):793-802. PubMed ID: 26685004
    [Abstract] [Full Text] [Related]

  • 9. Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience.
    Emma R, Morjaria JB, Fuochi V, Polosa R, Caruso M.
    Ther Adv Respir Dis; 2018 Jun; 12():1753466618808490. PubMed ID: 30354852
    [Abstract] [Full Text] [Related]

  • 10. Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563.
    Drugs R D; 2008 Jun; 9(2):125-30. PubMed ID: 18298130
    [Abstract] [Full Text] [Related]

  • 11. The clinical profile of benralizumab in the management of severe eosinophilic asthma.
    Menzella F, Lusuardi M, Galeone C, Facciolongo N, Zucchi L.
    Ther Adv Respir Dis; 2016 Dec; 10(6):534-548. PubMed ID: 27612492
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of reslizumab in patients with moderate to severe eosinophilic asthma.
    Lim HF, Nair P.
    Expert Rev Respir Med; 2015 Apr; 9(2):135-42. PubMed ID: 25578680
    [Abstract] [Full Text] [Related]

  • 13. Reslizumab in the treatment of inadequately controlled asthma in adults and adolescents with elevated blood eosinophils: clinical trial evidence and future prospects.
    Máspero J.
    Ther Adv Respir Dis; 2017 Aug; 11(8):311-325. PubMed ID: 28683596
    [Abstract] [Full Text] [Related]

  • 14. Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: Results of a single-centre observational study.
    Pelaia C, Busceti MT, Solinas S, Terracciano R, Pelaia G.
    Pulm Pharmacol Ther; 2018 Dec; 53():1-5. PubMed ID: 30217438
    [Abstract] [Full Text] [Related]

  • 15. Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab.
    Mukherjee M, Aleman Paramo F, Kjarsgaard M, Salter B, Nair G, LaVigne N, Radford K, Sehmi R, Nair P.
    Am J Respir Crit Care Med; 2018 Jan 01; 197(1):38-46. PubMed ID: 28915080
    [Abstract] [Full Text] [Related]

  • 16. Reslizumab (Cinqair) for severe eosinophilic asthma.
    Med Lett Drugs Ther; 2016 Jun 20; 58(1497):81-2. PubMed ID: 27305070
    [No Abstract] [Full Text] [Related]

  • 17. Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma.
    Katz LE, Gleich GJ, Hartley BF, Yancey SW, Ortega HG.
    Ann Am Thorac Soc; 2014 May 20; 11(4):531-6. PubMed ID: 24606022
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma.
    Matera MG, Rogliani P, Calzetta L, Cazzola M.
    Expert Opin Drug Metab Toxicol; 2018 Feb 20; 14(2):239-245. PubMed ID: 29268638
    [Abstract] [Full Text] [Related]

  • 19. The safety of mepolizumab for the treatment of asthma.
    Leung E, Al Efraij K, FitzGerald JM.
    Expert Opin Drug Saf; 2017 Mar 20; 16(3):397-404. PubMed ID: 28116937
    [Abstract] [Full Text] [Related]

  • 20. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma.
    Khatri S, Moore W, Gibson PG, Leigh R, Bourdin A, Maspero J, Barros M, Buhl R, Howarth P, Albers FC, Bradford ES, Gilson M, Price RG, Yancey SW, Ortega H.
    J Allergy Clin Immunol; 2019 May 20; 143(5):1742-1751.e7. PubMed ID: 30359681
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 54.